Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 484.89% and ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Experienced medical executive brings expansive knowledge in clinical development and medical affairs PHILADELPHIA, Jan. 8, 2025 /PRNewswire/ -- GEMMA Biotherapeutics ("GEMMABio") - a new ...

The move intensifies an ongoing legal battle, as Novo Nordisk joins its major competitor Eli Lilly in opposing a recent initiative by the Outsourcing Facilities Association to include liraglutide in ...

GEMMA Biotherapeutics ("GEMMABio") – a new therapeutics company founded by gene therapy pioneer Dr. Jim Wilson – today ...

Healthcare tech company H1 picked up Ribbon Health, a provider data management software company to broaden its reach into the health plan, provider system and digital health sectors. | Healthcare tech ...

ClearBridge Investments, an investment management company, released its “ClearBridge Large Cap Growth Strategy” fourth ...

In the latest trading session, Eli Lilly (LLY) closed at $773.29, marking a +1.07% move from the previous day. The stock outpaced the S&P 500's daily loss of 1.11%. On the other hand, the Dow ...

North Dakota lawmakers on Thursday will hear testimony on a bill to lower the price of insulin drugs and supplies for ...

A new trend gaining popularity among people trying to lose weight is microdosing the diabetes medication Ozempic.

Surgeons are collaborating with obesity medicine physicians, turning to GLP-1s to help high BMI patients qualify for surgery.

Ophthalmic diseases specialist Oculis Holding AG announced positive phase II data showing its serum-glucose corticoid kinase-2 activator OCS-05 protected nerve cells and improved vision in patients ...